Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry)

Clinical Research in Cardiology

Volumn 100, Issue 4, 2011, Pages 277-287

  Gitt, Anselm K ^a   Jünger, Claus ^a   Jannowitz, Christina ^b   Karmann, Barbara ^c   Senges, Jochen ^a   Bestehorn, Kurt ^b,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

^c Essex Pharma GmbH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Coronary heart disease; Drug treatment; Guideline adherence; High density lipoproteins; Hospital; Hypercholesterolemia; Risk stratification; Statins

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE REGISTRY; DRUG DOSE INCREASE; FEMALE; GERMANY; HEART FAILURE; HEART INFARCTION; HOSPITAL CARE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; SMOKING; STROKE;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOLOGY; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; GERMANY; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 79954447639     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0240-9     Document Type: Article

References (43)

1. G Assmann H Schulte P Cullen A Neiss K Bestehorn 2007 Treatment of hyperlipidemia in primary practise in Germany: sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus Exp Clin Endocrinol Diabetes 115 85 91 17318766 10.1055/s-2007-955094 1:CAS:528:DC%2BD2sXjvVynur8%3D (Pubitemid 46408114)
2. G Assmann H Schulte P Cullen U Seedorf 2007 Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study Eur J Clin Invest 37 925 932 18036028 10.1111/j.1365-2362.2007. 01888.x 1:STN:280:DC%2BD2snpvF2isw%3D%3D (Pubitemid 350151189)
3. G Bakris M Bohm G Dagenais HC Diener T Fujita P Gorelick SE Kjeldsen M Laakso G Mancia B Pitt A Sharma P Sleight K Teo T Unger M Weber B Williams F Zannad 2008 Cardiovascular protection for all individuals at high risk: evidence-based best practice Clin Res Cardiol 97 713 725 18726243 10.1007/s00392-008-0713-2
4. K Bestehorn C Jannowitz B Karmann D Pittrow W Kirch 2009 Characteristics, management and attainment of lipid target levels in patients enrolled in Disease Management Program versus those in routine care: LUTZ registry BMC Public Health 9 280 19653899 10.1186/1471-2458-9-280
5. K Bestehorn J Schäfer A Gitt C Jannowitz B Karmann FJ Sonntag A Weizel 2008 Leitliniengerechte Lipidtherapie und Zielwerterreichung bei Risikopatienten im klinischen Alltag. Rationale, Ziele und Design des LIMA-Registers MMW Fortschr Med 150 Suppl 135 141
6. B Bischoff S Silber BM Richartz L Pieper J Klotsche HU Wittchen 2006 Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany Clin Res Cardiol 95 405 412 16799879 10.1007/s00392-006-0399-2 1:STN:280:DC%2BD28vktlKqsg%3D%3D (Pubitemid 44137198)
7. Bohler S, Scharnagel H, Freisinger F, Stojakovic T, Glaesmer H, Klotsche J, Pieper L, Pittrow D, Kirch W, Schneider H, Stalla GK, Lehnert H, Zeiher AM, Silber S, Koch U, Ruf G, Marz W, Wittchen HU (2006) Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis. doi: 10.1016/j.atherosclerosis.2006.02.025
8. CP Cannon E Braunwald CH McCabe DJ Rader JL Rouleau R Belder SV Joyal KA Hill MA Pfeffer AM Skene the Pravastatin or Atorvastatin Evaluation, Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators 2004 Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495 1504 15007110 10.1056/NEJMoa040583 1:CAS:528:DC%2BD2cXjtVeqtr8%3D (Pubitemid 38477774)
9. JC Cohen E Boerwinkle TH Mosley Jr HH Hobbs 2006 Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 1264 1272 16554528 10.1056/NEJMoa054013 1:CAS:528:DC%2BD28Xislequr8%3D
10. RB D'Agostino Sr S Grundy LM Sullivan P Wilson 2001 Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation JAMA 286 180 187 11448281 10.1001/jama.286.2.180 (Pubitemid 32640849)
11. MH Davidson KC Maki TA Pearson RC Pasternak PC Deedwania JM McKenney GC Fonarow DJ Maron BJ Ansell LT Clark CM Ballantyne 2005 Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am J Cardiol 96 556 563 16098311 10.1016/j.amjcard.2005.04.019 (Pubitemid 41132774)
12. C Diehm A Schuster H Allenberg H Darius R Haberl S Lange D Pittrow B von Stritzky G Tepohl H Trampisch 2004 High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study Atherosclerosis 172 95 105 14709362 10.1016/S0021-9150(03)00204-1 1:CAS:528:DC%2BD2cXovVGj (Pubitemid 38058606)
13. T Fagan 1994 Remembering the lessons of basic pharmacology Arch Intern Med 154 1430 1431 8017997 10.1001/archinte.154.13.1430 1:STN:280: DyaK2c3ovVOjuw%3D%3D (Pubitemid 24208567)
14. Federal Statistical Office Leading causes for death in 2007. http://www-ec.destatis.de/csp/shop/sfg/bpm.html.cms.cBroker.cls?cmspath= struktur,vollanzeige.csp&ID=1022599. Accessed 12 Oct 2010
15. PD Friedmann AS Brett MF Mayo-Smith 1996 Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease Ann Intern Med 124 414 421 8554250 1:STN:280:DyaK287ltF2ntw%3D%3D (Pubitemid 26065073)
16. AK Gitt C Juenger C Jannowitz B Karmann J Senges K Bestehorn 2009 Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry Eur J Cardiovasc Prev Rehabil 16 438 444 19369876 10.1097/HJR. 0b013e32832a4e25
17. H Gohlke W Kubler P Mathes T Meinertz G Schuler DB Gysan G Sauer 2001 Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group Z Kardiol 90 148 149 11263006 10.1007/s003920170203 1:STN:280: DC%2BD3M7mtlagug%3D%3D (Pubitemid 32295410)
18. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 15249516 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
19. SK Hildemann C Barho B Karmann H Darius K Bestehorn 2007 Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice Curr Med Res Opin 23 713 719 17407627 10.1185/030079907X178702 1:CAS:528:DC%2BD2sXlsVymu7w%3D (Pubitemid 46631474)
20. Hildemann SK, Barho C, Karmann B, Darius H, Bode C (2008) Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Curr Med Res Opin 24:2777-2784
21. H Kanstrup JF Lassen L Heickendorff T Lauritzen ML Larsen 2004 Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients J Intern Med 255 367 372 14871460 10.1111/j.1365-2796.2003.01299.x 1:CAS:528:DC%2BD2cXislKmtbY%3D (Pubitemid 38315277)
22. JG Keevil MW Cullen R Gangnon PE McBride JH Stein 2007 Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002 Circulation 115 1363 1370 17353444 10.1161/CIRCULATIONAHA.106.645473 1:CAS:528:DC%2BD2sXislaisbo%3D (Pubitemid 46648371)
23. RH Knopp 1999 Drug treatment of lipid disorders N Engl J Med 341 498 511 10441607 10.1056/NEJM199908123410707 1:STN:280:DyaK1MzltlGjtQ%3D%3D (Pubitemid 29372891)
24. S Lange HJ Trampisch R Haberl H Darius D Pittrow A Schuster B von Stritzky G Tepohl JR Allenberg C Diehm 2005 Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level Atherosclerosis 178 351 357 15694945 10.1016/j. atherosclerosis.2004.09.003 1:CAS:528:DC%2BD2MXhtVyjur0%3D (Pubitemid 40193451)
25. MR Law NJ Wald AR Rudnicka 2003 Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis Br Med J 326 1423 1430 10.1136/bmj.326.7404.1423 1:CAS:528:DC%2BD3sXlvFCjsLY%3D
26. AK Marma DM Lloyd-Jones 2009 Systematic examination of the updated Framingham heart study general cardiovascular risk profile Circulation 120 384 390 19620502 10.1161/CIRCULATIONAHA.108.835470
27. JM McKenney 2004 Optimizing LDL-C lowering with statins Am J Ther 11 54 59 14704596 10.1097/00045391-200401000-00011
28. L Mosca 2007 Guidelines for prevention of cardiovascular disease in women: a summary of recommendations Prev Cardiol 10 19 25 17917527 10.1111/j.1520-037X.2007.07255.x
29. L Mosca AH Linfante EJ Benjamin K Berra SN Hayes BW Walsh RP Fabunmi J Kwan T Mills SL Simpson 2005 National study of physician awareness and adherence to cardiovascular disease prevention guidelines Circulation 111 499 510 15687140 10.1161/01.CIR.0000154568.43333.82 (Pubitemid 40204436)
30. NCEP ATP III Guidelines at A Glance Quick Desk Reference. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed 12 Oct 2010
31. L Ose FE Skjeldestad IJ Bakken A Levorsen EA Alemao DD Yin F Borgstrom L Jonsson 2006 Lipid management and cholesterol goal attainment in Norway Am J Cardiovasc Drugs 6 121 128 16555865 10.2165/00129784-200606020-00006 1:CAS:528:DC%2BD28XlvVSqu7c%3D
32. Ovbiagele B, Liebeskind DS, Kim D, Ali LK, Pineda S, Saver JL (2010) Prognostic value of Framingham Cardiovascular Risk Score in hospitalized stroke patients. J Stroke Cerebrovasc Dis
33. TA Pearson MA Denke PE McBride WP Battisti WE Brady J Palmisano 2005 A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial Mayo Clin Proc 80 587 595 15887425 10.4065/80.5.587 1:CAS:528:DC%2BD2MXkslKlsro%3D (Pubitemid 40628813)
34. SD Persell DM Lloyd-Jones DW Baker 2006 Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia J Gen Intern Med 21 171 176 16390501 (Pubitemid 43363674)
35. BM Psaty TD Koepsell D Lin NS Weiss DS Siscovick FR Rosendaal M Pahor CD Furberg 1999 Assessment and control for confounding by indication in observational studies J Am Geriatr Soc 47 749 754 10366179 1:STN:280: DyaK1M3pt1ejsw%3D%3D (Pubitemid 29266647)
36. J Ruof G Klein W Marz H Wollschlager A Neiss M Wehling 2002 Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns Prev Med 35 48 53 12079440 10.1006/pmed.2002.1050 1:CAS:528:DC%2BD38XkslagtLo%3D (Pubitemid 34762085)
37. L Ryden E Standl M Bartnik G Van den Berghe J Betteridge MJ de Boer F Cosentino B Jonsson M Laakso K Malmberg S Priori J Ostergren J Tuomilehto I Thrainsdottir I Vanhorebeek M Stramba-Badiale P Lindgren Q Qiao SG Priori JJ Blanc A Budaj J Camm V Dean J Deckers K Dickstein J Lekakis K McGregor M Metra J Morais A Osterspey J Tamargo JL Zamorano JW Deckers M Bertrand B Charbonnel E Erdmann E Ferrannini A Flyvbjerg H Gohlke JR Juanatey I Graham PF Monteiro K Parhofer K Pyorala I Raz G Schernthaner M Volpe D Wood 2007 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 88 136 17220161 10.1093/eurheartj/ehm124 1:CAS:528:DC%2BD2sXitlaiur8%3D (Pubitemid 47355991)
38. Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D (2009) Systematic review: comparative effectiveness and harms of combinations of lipid-modifying agents and high-dose statin monotherapy. Ann Intern Med, p 151 [Epub ahead of print]
39. S Silber F Jarre D Pittrow J Klotsche L Pieper A Zeiher H Wittchen for the DETECT Study Group Cardiovascular risk assessment in primary care (DETECT) 2008 What is the concordance between physician assessment and established risk scores? Med Klin 103 9 638 645 10.1007/s00063-008-1103-2
40. SC Smith Jr J Allen SN Blair RO Bonow LM Brass GC Fonarow SM Grundy L Hiratzka D Jones HM Krumholz L Mosca RC Pasternak T Pearson MA Pfeffer KA Taubert 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2363 2372 16702489 10.1161/CIRCULATIONAHA.106.174516 (Pubitemid 43947981)
41. PG Steg DL Bhatt PW Wilson R D'Agostino Sr EM Ohman J Rother CS Liau AT Hirsch JL Mas Y Ikeda MJ Pencina S Goto 2007 One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 1197 1206 17374814 10.1001/jama.297.11.1197 1:CAS:528:DC%2BD2sXlvVWmt74%3D (Pubitemid 46465728)
42. RJ Valuck SA Williams M MacArthur JJ Saseen KV Nair M McCollum JE Ensor 2003 A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization Clin Ther 25 2936 2957 14693317 10.1016/S0149-2918(03)80346-6 (Pubitemid 37510602)
43. H Völler R Reibis D Pittrow C Jannowitz K Wegscheider B Karmann K Bestehorn 2009 Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: risk factors, treatment and target level attainment Curr Med Res Opin 25 879 890 19254205 10.1185/03007990902801360